ReviewCNS drugs2015
Targeting the Serotonin 5-HT7 Receptor in the Search for Treatments for CNS Disorders: Rationale and Progress to Date.
Review in CNS drugs, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 129 citations in OpenAlex.
- Efficacy and Safety of Hormone Replacement Combined With Escitalopram in the Treatment of Chronic Insomnia in Perimenopausal Women: A Randomized Controlled Trial.CNS neuroscience & therapeutics · 2025Trial
- Dually Acting Ligands Targeting Serotonin Receptors: Implications in CNS Disorders.Journal of medicinal chemistry · 2026Review
- Uncovering novel therapeutics for schizophrenia: a multitarget approach using the CANDO platform.bioRxiv : the preprint server for biology · 2026Article
- Dual-Selective Terahertz-Nanodisc Metasurfaces for Exploring Neurotransmitter Dynamics beyond Spectral Limitations.Advanced materials (Deerfield Beach, Fla.) · 2025Article
- Compound PZ-1262, a 4-isoquinoline-sulfonamide analog of Brexpiprazole, produces potential antidepressant, anxiolytic and procognitive effects in rodent models.Pharmacological reports : PR · 2025Article
- Article
- Targeting serotonin receptors with phytochemicals - an in-silico study.Scientific reports · 2024Article
- DSP-6745, a novel 5-hydroxytryptamine modulator with rapid antidepressant, anxiolytic, antipsychotic and procognitive effects.Psychopharmacology · 2024Article
- Content analysis of Reddit posts about coadministration of selective serotonin reuptake inhibitors and psilocybin mushrooms.Psychopharmacology · 2024Article
- Neuroprotective and Neurite Outgrowth Stimulating Effects of New Low-Basicity 5-HTNeurochemical research · 2024Article
- The trace amine-associated receptor 1 agonists - non-dopaminergic antipsychotics or covert modulators of D2 receptors?Journal of psychopharmacology (Oxford, England) · 2024Review
- Successful Challenge With Brexpiprazole for Idiopathic Hypersomnia in a Patient With Bipolar Disorder: A Case Report.Cureus · 2024Article
- Global research in schizophrenia and serotonin: a bibliometric analysis.Frontiers in psychiatry · 2024Review
- Functional Implications and Clinical Potential of MicroRNAs in Irritable Bowel Syndrome: A Concise Review.Digestive diseases and sciences · 2023Review
- Central nervous system effects of 5-HTMolecular medicine (Cambridge, Mass.) · 2022Review
- Serotonin receptors in epilepsy: Novel treatment targets?Epilepsia open · 2022Review
- Expression of the Human Serotonin 5-HTCells · 2022Article
- Design and discovery of a high affinity, selective and β-arrestin biased 5-HTMedicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2022Article
- 5-HT Receptors and Temperature Homeostasis.Biomolecules · 2021Review
- The Structural Determinants for αMolecules (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The 5-HT7 (5-hydroxytryptamine 7, serotonin 7) receptor is one of the most recently identified members of the serotonin receptor family. Pharmacological tools, including selective antagonists and, more recently, agonists, along with 5-HT7 receptor (5-HT7R) knock-out mice have revealed the involvement of this receptor in central nervous system processes. Its well-established role in controlling body temperature and regulating sleep and circadian rhythms has implicated this receptor in mood disorders. Thus, the 5-HT7R has gained much attention as a possible target for the treatment of depression. Although preclinical data support the antidepressant-like actions of 5-HT7R antagonists, their clinical efficacy has not been yet established. Other evidence has implicated the 5-HT7R in learning and memory. Preclinical findings suggest that blockade of this receptor may be beneficial against schizophrenia-like cognitive deficits. Other possible indications include nociception, epilepsy, migraine, autism spectrum disorders, and Rett Syndrome. However, the question is whether the beneficial effects may be achieved by activation or blockade of 5-HT7Rs. Hence, this review briefly summarises the recent findings on the role of 5-HT7Rs and their ligands in CNS disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.